Kestra Medical Technologies (NASDAQ:KMTS) Director Jeffrey Lawrence Schwartz Sells 3,890 Shares of Stock

Posted by Brian Himes on Sep 11th, 2026

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS – Get Free Report) Director Jeffrey Lawrence Schwartz sold 3,890 shares of the stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $25.18, for a total transaction of $97,950.20. Following the completion of the sale, the director directly owned 7,019 shares in the company, valued at approximately $176,738.42. This represents a 35.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Trading Down 2.1%

KMTS opened at $23.57 on Friday. Kestra Medical Technologies, Ltd. has a one year low of $17.34 and a one year high of $30.00. The company has a market cap of $1.38 billion, a P/E ratio of -9.74 and a beta of 0.62. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41. The business’s 50-day simple moving average is $25.42 and its 200-day simple moving average is $22.71.

Kestra Medical Technologies (NASDAQ:KMTS – Get Free Report) last issued its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.08). Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%.The firm had revenue of $28.64 million for the quarter. As a group, equities research analysts expect that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current fiscal year.

More Kestra Medical Technologies News

Here are the key news stories impacting Kestra Medical Technologies this week:

Positive Sentiment: Kestra appointed Daniel Finney as Vice President of Research & Development and added him to the executive leadership team. Finney has more than 20 years of Class III medical-device experience and previously led Kestra’s new product development efforts. He will oversee innovation for the Cardiac Recovery System platform, including strategic partnerships and artificial-intelligence initiatives. Kestra Names Daniel Finney Vice President of Research & Development
Neutral Sentiment: Reported short interest was zero shares as of September 10, indicating no measurable short-selling pressure based on the filing data. However, the figure provides little incremental insight because it was also reported as zero in the prior period.
Negative Sentiment: Four directors disclosed sales totaling about 16,424 shares worth approximately $414,000. The transactions reduced their individual holdings by roughly 9% to 48%. All four sales were explicitly made to cover tax-withholding obligations tied to vested equity awards, which makes them less bearish than discretionary open-market selling, but the cluster of transactions may still pressure sentiment. SEC insider transaction filing
Negative Sentiment: Kestra’s latest reported quarter included an adjusted loss of $0.67 per share, worse than the $0.59 analyst consensus, alongside $28.64 million in revenue. The company remains unprofitable, increasing investor sensitivity to execution, product adoption and commercialization risks.

Hedge Funds Weigh In On Kestra Medical Technologies

Hedge funds have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. raised its holdings in shares of Kestra Medical Technologies by 43.5% during the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after purchasing an additional 474 shares during the period. BNP Paribas Financial Markets grew its position in shares of Kestra Medical Technologies by 148.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after buying an additional 1,638 shares during the last quarter. Daiwa Securities Group Inc. bought a new stake in shares of Kestra Medical Technologies during the 4th quarter valued at about $72,000. Brown Brothers Harriman & Co. raised its stake in Kestra Medical Technologies by 26.8% during the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after acquiring an additional 656 shares during the period. Finally, New York State Common Retirement Fund bought a new position in Kestra Medical Technologies in the second quarter worth about $93,000.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Weiss Ratings downgraded Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, August 31st. JPMorgan Chase & Co. initiated coverage on Kestra Medical Technologies in a research report on Monday, August 10th. They set an “overweight” rating and a $30.00 price objective for the company. Oppenheimer began coverage on Kestra Medical Technologies in a research note on Tuesday, July 21st. They issued a “market perform” rating for the company. Wall Street Zen raised shares of Kestra Medical Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Wolfe Research set a $30.00 target price on shares of Kestra Medical Technologies in a research report on Wednesday, July 15th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $28.14.

View Our Latest Stock Report on KMTS

Kestra Medical Technologies Company Profile

(Get Free Report)

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.